Citrate anticoagulation during plasma exchange in a patient with thrombotic thrombocytopenic purpura: short heparin-free hemodialysis helps to attenuate citrate load.
The treatment of thrombotic thrombocytopenic purpura requires plasma exchange using fresh frozen plasma as a replacement solution once or even twice daily. If citrate anticoagulation is needed, the citrate load (both from fresh frozen plasma and citrate as an anticoagulant) can be significant, causing metabolic complications. The aim of our report is to present our experience with citrate anticoagulation in a patient with thrombotic thrombocytopenic purpura treated with daily membrane plasma exchange. Twenty-six plasma exchange procedures were performed during 20 days of treatment in a 46-year-old female. The blood flow was 98 +/- 8 mL/min; 4% trisodium citrate was infused into the arterial line (134 +/- 11 mL/h) and 1 M CaCl2 into the venous line (11.4 +/- 1.8 mL/h). Fresh frozen plasma (first 7 procedures) or cryo-poor plasma (19 procedures) were used as a replacement solution, 3176 +/- 536 mL per procedure. A total of 88,930 mL of plasma was exchanged. No serious side-effects occurred. iCa before plasma exchange was significantly higher than afterwards (1.23 +/- 0.12 vs. 1.12 +/- 0.12, P = 0.0047). Significant alkalosis occurred after three plasma exchanges (pH 7.64, bicarbonate 36.2 mmol/L), and was corrected by 3-h heparin-free hemodialysis with dialysate as follows: K 4.0 mmol/L, calcium 1.5 mmol/L, and bicarbonate set to 24 mmol/L. After dialysis, pH was 7.45 and bicarbonate 29.4 mmol/L. Another (2-h) heparin-free hemodialysis procedure was repeated after six plasma exchanges. Citrate anticoagulation can be safely performed in patients treated with plasma exchange once or twice daily. Periodically performed short heparin-free hemodialysis can correct metabolic alkalosis and attenuate the citrate load.
Buturović-Ponikvar
Jadranka
J
Department of Nephrology, University Medical Center Ljubljana, University of Ljubljana, Ljubljana, Slovenia. jadrankabuturovic@mf.uni-lj.si
Pernat
Andreja Marn
AM
Ponikvar
Rafael
R
D000471:Alkalosis / Q000209:etiology / Q000628:therapy; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D002122:Calcium Chloride / Q000008:administration & dosage; D019343:Citric Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D015312:Hemodialysis Solutions / Q000627:therapeutic use; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008875:Middle Aged; D010949:Plasma; D010951:Plasma Exchange / Q000009:adverse effects; D011188:Potassium / Q000627:therapeutic use; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy*; D006435:Renal Dialysis / Q000379:methods*
D000925:Anticoagulants; D001639:Bicarbonates; D015312:Hemodialysis Solutions; D019343:Citric Acid; D002122:Calcium Chloride; D011188:Potassium; D002118:Calcium